CDSCO panel rejects Pfizer Products India Local Clinical Trial Waiver Proposal for Elranatamab solution for injection

The committee noted that the drug has an accelerated approval (conditional approval) in the USFDA for proposed indication based on Phase II clinical trial data and the trial is ongoing.

Elranatamab is a bispecific antibody used to treat adults with relapsed or refractory multiple myeloma.

Elranatamab is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager. It is a humanized immunoglobulin 2-alanine kappa antibody derived from two monoclonal antibodies (mAbs), an anti-BCMA mAb and an anti-CD3 mAb, each of which contributes one heavy chain and one light chain to drug structure.

Elranatamab is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma. In the US, it is approved in patients who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

At the recent SEC meeting for Oncology held on 3rd and 4th April 2024, the expert panel reviewed the proposal presented by the drug major Pfizer for granting permission to import and market Elranatamab solution for injection 44 mg/1.1 mL (40 mg/mL) and 76 mg/1.9 mL(40 mg/mL) along with the request for local clinical trial waiver.

After detailed deliberation, the committee did not consider the firm’s request for waiver of the local clinical trial for grant of permission to import and market Elranatamab solution for injection.

Also Read: CDSCO Panel Approves Eli Lilly's protocol amendment proposal for Adjuvant Imlunestrant vs Standard Adjuvant study